27932568|t|Targeting HIF2 in Clear Cell Renal Cell Carcinoma
27932568|a|Inactivation of the von Hippel-Lindau tumor-suppressor protein (pVHL) is the signature "truncal" event in clear cell renal cell carcinoma, which is the most common form of kidney cancer. pVHL is part of a ubiquitin ligase the targets the α subunit of the hypoxia-inducible factor (HIF) transcription factor for destruction when oxygen is available. Preclinical studies strongly suggest that deregulation of HIF, and particularly HIF2, drives pVHL -defective renal carcinogenesis. Although HIF2α was classically considered undruggable, structural and chemical work by Rick Bruick and Kevin Gardner at University of Texas Southwestern laid the foundation for the development of small molecule direct HIF2α antagonists (PT2385 and the related tool compound PT2399) by Peloton Therapeutics that block the dimerization of HIF2α with its partner protein ARNT1. These compounds inhibit clear cell renal cell carcinoma growth in preclinical models, and PT2385 has now entered the clinic. Nonetheless, the availability of such compounds, together with clustered regularly interspaced short palindromic repeat (CRISPR)-based gene editing approaches, has revealed a previously unappreciated heterogeneity among clear cell renal carcinomas and patient -derived xenografts with respect to HIF2 dependence, suggesting that predictive biomarkers will be needed to optimize the use of such agents in the clinic.
27932568	0	9	Targeting	T169	C1521840
27932568	10	14	HIF2	T116,T123	C1436532
27932568	18	49	Clear Cell Renal Cell Carcinoma	T191	C0279702
27932568	70	112	von Hippel-Lindau tumor-suppressor protein	T116,T126	C1566585
27932568	114	118	pVHL	T116,T126	C1566585
27932568	127	152	signature "truncal" event	T033	C0243095
27932568	156	187	clear cell renal cell carcinoma	T191	C0279702
27932568	222	235	kidney cancer	T191	C1378703
27932568	237	241	pVHL	T116,T126	C1566585
27932568	255	271	ubiquitin ligase	T116,T126	C0077678
27932568	276	283	targets	T169	C1521840
27932568	288	297	α subunit	T116	C0599220
27932568	305	356	hypoxia-inducible factor (HIF) transcription factor	T116,T123	C1528322
27932568	361	372	destruction	T052	C1948029
27932568	399	410	Preclinical	T080	C1709630
27932568	411	418	studies	T062	C0008972
27932568	441	453	deregulation	T049	C1514542
27932568	457	460	HIF	T116,T123	C1528322
27932568	479	483	HIF2	T116,T123	C1436532
27932568	492	496	pVHL	T116,T126	C1566585
27932568	508	528	renal carcinogenesis	T191	C1378703
27932568	539	544	HIF2α	T116,T123	C0538487
27932568	572	583	undruggable	T080	C0205556
27932568	617	628	Rick Bruick	T170	C0805191
27932568	633	646	Kevin Gardner	T170	C0805191
27932568	650	682	University of Texas Southwestern	T073,T092	C0041740
27932568	726	740	small molecule	T109	C1328819
27932568	748	765	HIF2α antagonists	T120	C0243076
27932568	767	773	PT2385	T109,T121	C3896783
27932568	804	810	PT2399	T120	C0243076
27932568	815	835	Peloton Therapeutics	T093	C0815266
27932568	841	846	block	T169	C0332206
27932568	851	863	dimerization	T044	C1323327
27932568	867	872	HIF2α	T116,T123	C0538487
27932568	890	903	protein ARNT1	T116,T123	C1506870
27932568	921	967	inhibit clear cell renal cell carcinoma growth	T043	C1512773
27932568	971	989	preclinical models	T170	C1514292
27932568	995	1001	PT2385	T109,T121	C3896783
27932568	1022	1028	clinic	T073,T093	C0442592
27932568	1063	1077	such compounds	T121	C1254351
27932568	1093	1149	clustered regularly interspaced short palindromic repeat	T114	C3658200
27932568	1151	1157	CRISPR	T114	C3658200
27932568	1165	1188	gene editing approaches	T063	C4277689
27932568	1216	1243	unappreciated heterogeneity	T080	C0019409
27932568	1250	1277	clear cell renal carcinomas	T191	C0279702
27932568	1282	1289	patient	T101	C0030705
27932568	1299	1309	xenografts	T061	C0520484
27932568	1326	1330	HIF2	T116,T123	C1436532
27932568	1359	1380	predictive biomarkers	T123	C0041366
27932568	1399	1407	optimize	T052	C2698650
27932568	1419	1430	such agents	T121	C1254351
27932568	1438	1444	clinic	T073,T093	C0442592